| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | MFSD2 |
| WB Predicted band size | 60 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human MFSD2A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于MFSD2A抗体的重要文献概览：
---
1. **文献名称**：Mfsd2a is critical for the formation and function of the blood-brain barrier
**作者**：Ben-Zvi A, et al.
**摘要**：首次揭示MFSD2A通过转运omega-3脂肪酸DHA维持血脑屏障完整性，其抗体被用于验证内皮细胞特异性表达及功能缺失模型中的蛋白定位变化。
---
2. **文献名称**：Mutations in MFSD2A, encoding a lysolipid transporter for docosahexaenoic acid, cause microcephaly and intellectual disability
**作者**：Guemez-Gamboa A, et al.
**摘要**：通过患者基因测序发现MFSD2A突变导致小头畸形，利用特异性抗体证实突变造成蛋白表达异常，揭示其在神经发育中脂质转运的关键作用。
---
3. **文献名称**：Structural basis of omega-3 fatty acid transport across the blood-brain barrier
**作者**：Chan JP, et al.
**摘要**：通过冷冻电镜解析MFSD2A蛋白结构，抗体被用于实验验证其与脂质配体的结合模式，阐明DHA跨血脑屏障转运的分子机制。
---
**备注**：以上文献均发表于《Nature》或《Cell》等高影响力期刊，建议通过PubMed/Google Scholar输入标题或作者名获取全文。若需实验用抗体信息，可参考文内Methods部分或商业抗体平台(如Abcam/Santa Cruz)的产品引用文献。
The MFSD2A (Major Facilitator Superfamily Domain Containing 2A) antibody is a critical tool for studying the function and expression of the MFSD2A protein, a transmembrane transporter belonging to the major facilitator superfamily. MFSD2A is primarily expressed in the endothelium of the blood-brain barrier (BBB) and plays a vital role in transporting essential lipids, such as docosahexaenoic acid (DHA), into the brain. It is also implicated in maintaining BBB integrity by regulating vesicular transcytosis. Dysregulation of MFSD2A has been linked to neurological disorders, including cognitive deficits and neurodevelopmental impairments.
The antibody enables researchers to detect MFSD2A in various experimental settings, such as Western blotting, immunohistochemistry, and flow cytometry, aiding in the investigation of its tissue distribution, expression levels, and interactions. Studies using MFSD2A antibodies have revealed its reduced expression in aging brains and certain disease models, such as Alzheimer’s disease and stroke. Additionally, genetic knockout models validated by antibody-based assays highlight MFSD2A’s role in lipid homeostasis and neuroprotection.
Understanding MFSD2A’s mechanisms through antibody-mediated research holds promise for developing therapies targeting BBB dysfunction or lipid metabolism disorders. Its specificity and reliability make it indispensable for both basic and translational neuroscience studies.
×
